<DOC>
	<DOC>NCT01927120</DOC>
	<brief_summary>IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).</brief_summary>
	<brief_title>In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis</brief_title>
	<detailed_description>1) Determine if a GVHD prophylaxis regimen of IL-2/SIR/TAC enhances in vivo Treg differentiation and growth; 2) Study the safety and effects of IL-2/SIR/TAC on the incidence of acute and chronic GVHD; 3) Evaluate the influence of dual IL-2 supplementation and mammalian target of rapamycin (mTOR) inhibition on T cell-specific signaling pathways and the polarization of emerging T helper cells.</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients must have an available 8/8 human leukocyte antigen (HLA)A, B, C, and DRB1 matchedrelated or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft. Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, or myeloproliferative neoplasms requiring a matched allogeneic HSCT. Acute Leukemia (AML or ALL) must be in complete remission defined as: &lt;5% marrow blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow &gt;20% cellular, and peripheral absolute neutrophil count &gt;1000/µL (platelet recovery is not required). Myelodysplasia (MDS) and chronic myeloid leukemia (CML): Must have &lt;5% marrow blasts. Myeloproliferative neoplasms (MPN): Must have &lt;5% peripheral / marrow blasts. Adequate vital organ function: 1. Left ventricular ejection fraction (LVEF) ≥ 45% by multi gated acquisition (MUGA) scan or ECHO 2. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and adjusted diffusing lung capacity oxygenation (DLCO) ≥ 50% of predicted values on pulmonary function tests 3. Transaminases (AST, ALT) &lt; 2 times upper limit of normal values 4. Creatinine clearance ≥ 50 cc/min. Performance status: Karnofsky Performance Status Score ≥ 80% Donor eligibility: Eligible donors will include healthy sibling, relative or unrelated donors that are matched with the patient at HLAA, B, C, and DRB1 by high resolution typing. Active infection not controlled with appropriate antimicrobial therapy History of HIV, hepatitis B, or hepatitis C infection Antithymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered within 14 days before or planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days after HCT. Hypersensitivity to recombinant human IL2 Chronic lymphocytic leukemia, Hodgkin lymphoma, and nonhodgkin lymphoma are excluded as these malignancies may express the IL2 receptor and pose a potential growth signal to any present disease. Sorror's comorbidity factors with total score &gt;4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GVHD</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Hematopoietic Cell Transplant</keyword>
</DOC>